USPTO Examiner HASTINGS ALISON AZAR - Art Unit 1627

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18422500Carboxylic Acid Containing Azetidinyl Compounds for the Treatment of Neurodegenerative DiseasesJanuary 2024September 2025Allow2011NoNo
18479410COMBINATION THERAPY USING RIBOCICLIB AND AN AROMATASE INHIBITOR FOR THE TREATMENT OF HR+ BREAST CANCEROctober 2023December 2025Allow2640YesYes
18469975COMBINATION THERAPY USING RIBOCICLIB AND FULVESTRANT FOR THE TREATMENT OF HR+ BREAST CANCERSeptember 2023December 2025Allow2740YesYes
18261832USE OF PYRIDO[1,2-A]PYRIMIDONE ANALOGUEJuly 2023March 2026Allow3210NoNo
18126355PLEUROMUTILIN DERIVATIVE CONTAINING THIAZOLE-PYRIDINE BENZYL QUATERNARY AMMONIUM SALT SIDE CHAIN AND PREPARATION METHOD AND USE THEREOFMarch 2023January 2025Allow2221NoNo
18188796TREATMENT OF BENIGN PROSTATIC HYPERTROPHY WITH CAPSINOIDSMarch 2023February 2025Allow2310YesNo
181861583-TETRAZOLYLMETHYL-1,3,5-TRIAZIN-2,4-DIONE COMPOUND INHIBITING CORONAVIRUS 3CL PROTEASE ACTIVITY AND PREPARATION METHOD AND USE THEREOFMarch 2023December 2024Allow2111NoNo
18122278METHODS OF TREATMENT AND PREVENTION USING 4-DEOXY-L-ERYTHRO-5-HEXOSEULOSE URONIC ACIDMarch 2023March 2025Allow2520YesNo
18114104SOLID FORMS OF (S)-1-((2',6-BIS(DIFLUOROMETHYL)-[2,4'-BIPYRIDIN]-5-YL)OXY)-2,4-DIMETHYLPENTAN-2-AMINE AND SALTS THEREOFFebruary 2023March 2025Allow2510NoNo
18114050METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF AN AAK1 INHIBITORFebruary 2023January 2025Allow2310NoNo
18169423HETEROCYCLIC COMPOUNDS AS BTK INHIBITORSFebruary 2023October 2025Abandon3210NoNo
18165776HYDROXYSTEROID COMPOUNDSFebruary 2023May 2025Abandon2701NoNo
18160690NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOFJanuary 2023January 2026Allow3610NoNo
18100412SOLID FORMS COMPRISING (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE AND SALTS THEREOF, AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAMEJanuary 2023November 2025Allow3410NoNo
18156186COMPOSITIONS FOR TREATING CMT AND RELATED DISORDERSJanuary 2023December 2025Abandon3520NoNo
17909179ALPHA SUBSTITUTED STAT INHIBITORS AND COMPOSITIONS THEREOFDecember 2022March 2026Abandon4210NoNo
17989956SELF-ASSEMBLED COMPLEX CONTAINING COPPER IONSNovember 2022October 2025Allow3510NoNo
179224055-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITYOctober 2022January 2026Allow3810NoNo
17997335BCL-2 PROTEIN INHIBITORSOctober 2022February 2026Abandon4010NoNo
17996821ACYCLIC CUCURBITURILS, METHODS OF MAKING SAME, AND USES THEREOFOctober 2022March 2026Abandon4110NoNo
17918497PULMONARY FIBROSIS MEDICINE CONTAINING PYRAZOLE DERIVATIVEOctober 2022February 2026Allow4020NoNo
17914671CRYSTAL FORM OF FREE ALKALI OF NITROGEN-CONTAINING AROMATIC DERIVATIVESSeptember 2022December 2025Abandon3910NoNo
17913976MATERIALS AND METHODS FOR IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT-TARGETED CANCER THERAPYSeptember 2022December 2025Allow3910NoNo
17622287INHIBITORS OF PRC1 FOR TREATMENT OF CANCERSeptember 2022February 2026Abandon5010NoNo
17905847OXADIAZOLE DERIVATIVESeptember 2022January 2026Allow4020YesNo
17909709AMPHIPHILIC ALGINATE-OLEIC ACID MACROMOLECULES AND PROCESS FOR PREPARATION THEREOFSeptember 2022October 2025Allow3710NoNo
17908752HEPATITIS B CAPSID ASSEMBLY MODULATORSSeptember 2022September 2025Abandon3601NoNo
17904822TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USEAugust 2022April 2025Allow3110NoNo
17866453METHODS AND COMPOSITIONS FOR TREATING CHEMOTHERAPY-INDUCED DIARRHEAJuly 2022January 2026Allow4210YesNo
17843774PHARMACEUTICAL COMBINATION OF ANTIVIRAL AGENTS TARGETING HBV AND/OR AN IMMUNE MODULATOR FOR TREATMENT OF HBVJune 2022January 2026Abandon4310NoNo
17786765CRYSTALS OF 3-HYDROXY-N'-(1,3-DIMETHYLBUTYLIDENE)-2-NAPHTHOIC ACID HYDRAZIDE AND PRODUCTION METHOD FOR THE SAMEJune 2022June 2025Allow3610NoNo
17757511COMBINATIONSJune 2022August 2025Abandon3810NoNo
17782870SMALL-MOLECULE COVALENT INHIBITION OF RAL GTPASESJune 2022August 2025Abandon3810NoNo
17831617COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCERJune 2022December 2025Abandon4310NoNo
17830215ALKYNYL-(HETEROARYL)-CARBOXAMIDE HCN1 INHIBITORSJune 2022September 2025Allow3910NoNo
17780971DEUTERIUM-ENRICHED SUBSTITUTED PHENOXYPHENYL ACETIC ACIDS AND ACYLSULFONAMIDESMay 2022September 2025Allow4020YesNo
17777881ADENOSINE RECEPTOR ANTAGONIST COMPOUNDSMay 2022December 2025Allow4310NoNo
17741989TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORSMay 2022September 2025Allow4011NoNo
17741206ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOFMay 2022April 2025Allow3510NoNo
17775133PAPD5 Inhibition As A Treatment For Dyskeratosis Congenita, Aplastic Anemia And Myelodysplastic Syndrome Caused By Reduced Telomerase RNA LevelsMay 2022October 2025Abandon4110NoNo
17773498TARGETING P73 FOR CANCERS RESISTANT TO BH3 MIMETICSApril 2022March 2026Abandon4730NoNo
17729929INHIBITORS OF RAF KINASESApril 2022November 2025Abandon4310NoNo
17771527SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORSApril 2022August 2025Allow4021NoNo
17767408HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASESApril 2022October 2025Allow4330NoNo
17630114IRAK4 KINASE INHIBITOR AND PREPARATION METHOD THEREFORApril 2022November 2025Allow4621YesNo
17767270PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITORSApril 2022September 2025Allow4221YesNo
17712001METHODS USING HDAC11 INHIBITORSApril 2022July 2025Allow3911YesNo
16304935METHODS FOR TREATING SMARCB1 DEFICIENT CANCER OR PAZOPANIB RESISTANT CANCERMarch 2022August 2025Abandon6010NoNo
17638398HALOGENATED COMPOUNDS, PROCESS AND USES THEREOFFebruary 2022November 2025Abandon4510YesNo
17633307Combination Therapy For Treatment Of CancerFebruary 2022January 2026Allow4821NoNo
17592870PROGESTERONE ANALOGS AND USES RELATED THERETOFebruary 2022July 2025Allow4120NoNo
17592426COMPOSITIONS FOR THE TREATMENT OF CHRONIC VULVAL AND PERINEAL PAIN AND SYMPTOMS AND CONDITIONS ASSOCIATED THEREWITHFebruary 2022September 2025Allow4440NoYes
17597939HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCERJanuary 2022May 2025Allow3911NoNo
176306736,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCERJanuary 2022August 2025Allow4211NoNo
17628814Lacosamide for the Treatment of ADD/ADHDJanuary 2022October 2025Abandon4510NoNo
17579514METHODS OF TREATING HYPERCHOLESTEROLEMIAJanuary 2022July 2025Abandon4210NoNo
175770182'-ISOPROPYL-SPIRO (3,3'-PYRROLIDINE OXINDOLE) LIVER X RECEPTOR REGULATOR, PREPARATION METHOD THEREFOR, AND USE THEREOFJanuary 2022May 2025Allow4011NoNo
17566371COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERSDecember 2021June 2025Abandon4210NoNo
17596830TYROSINE KINASE INHIBITOR CONJUGATESDecember 2021October 2025Abandon4611NoNo
17596721SALTS OF A COMPOUND, CRYSTAL FORMS OF THE SALTS AND PREPARATION METHOD AND USE THEREOFDecember 2021June 2025Abandon4210NoNo
17596488SMARCA DEGRADERS AND USES THEREOFDecember 2021November 2025Allow4721YesNo
17258447PHARMACEUTICAL COMPOSITION FOR PREVENTING DIABETES AND USE THEREOFJanuary 2021July 2025Abandon5410NoNo

Appeals Overview

No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.

Examiner HASTINGS, ALISON AZAR - Prosecution Strategy Guide

Executive Summary

Examiner HASTINGS, ALISON AZAR works in Art Unit 1627 and has examined 7 patent applications in our dataset. With an allowance rate of 14.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 47 months.

Allowance Patterns

Examiner HASTINGS, ALISON AZAR's allowance rate of 14.3% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by HASTINGS, ALISON AZAR receive 1.14 office actions before reaching final disposition. This places the examiner in the 13% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by HASTINGS, ALISON AZAR is 47 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +100.0% benefit to allowance rate for applications examined by HASTINGS, ALISON AZAR. This interview benefit is in the 100% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 50.0% of cases where such amendments are filed. This entry rate is in the 74% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Petition Practice

When applicants file petitions regarding this examiner's actions, 150.0% are granted (fully or in part). This grant rate is in the 97% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.